Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom

The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY | LLY Price Prediction) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim.

The Setup: A Relief Bounce Into a Weak Window

Lilly closed Monday at $966.99, up 2.9% over the past month and 31.6% over the past year, yet still down 10.0% year to date. That mismatch between a hot tape and a red YTD line is exactly what the “Sell in May” crowd hunts for.

The catalyst was a blowout Q1 report. Revenue hit $19.799 billion, growing 55.55% year over year, with non-GAAP EPS of $8.55 beating consensus by 25.88%. Mounjaro delivered $8.662 billion (+125%) and Zepbound added $4.160 billion (+80%). Management raised full-year revenue guidance to $82.0 billion to $85.0 billion.

One Reddit summary captured the mood: “Even with lower prices, demand keeps ripping.” Sentiment spiked to 85 (very bullish) on April 30, then faded to neutral within 72 hours, a classic relief-bounce signature.

Why the Trim Case Has Teeth

Realized prices fell 13% even as volume jumped 65%, a margin headwind that worsens with the Mounjaro NRDL listing in China and Zepbound cash-pay cuts. Drug pricing rhetoric tends to flare through summer political cycles. The franchise is concentrated, valuation is rich at a 34 P/E, and the Lilly Endowment disposed of 15,828 shares on May 6 near $995.

The Counter: Don’t Sell the Compounder

CEO David Ricks described the pipeline this way: “Foundayo will meaningfully expand the number of people who can benefit from GLP-1s.” Orforglipron beat oral semaglutide head to head in The Lancet, retatrutide is advancing, and four acquisitions deepen the bench. Four directors have systematically added shares at $1,036.05, $989.12, and $919.90. The analyst consensus target stands at $1,209.14 with 24 Buy, six Hold, and one Sell ratings.

How Long-Term Holders Might Frame It

Research-oriented frameworks suggest trimming a slice of the recent bounce while keeping the core position intact, using covered calls to monetize elevated post-rally volatility, mapping a re-entry zone near the 200-day moving average or the prior base, and applying stop-loss discipline rather than a full exit. This is a cleaner seasonal trim case than most mega-cap compounders, but selling a category-defining franchise on a calendar effect rarely ages well. The bounce offers room for tactical positioning while preserving core franchise exposure. Keep an eye on the stock heading into the December 7, 2026, Investment Community Meeting.